tiprankstipranks
Trending News
More News >
Beam Therapeutics price target lowered to $55 from $78 at Guggenheim
PremiumThe FlyBeam Therapeutics price target lowered to $55 from $78 at Guggenheim
5d ago
Vertex Pharmaceuticals: Hold Rating Amid Revenue Misses, Pipeline Challenges, and Slow Product Transitions
Premium
Ratings
Vertex Pharmaceuticals: Hold Rating Amid Revenue Misses, Pipeline Challenges, and Slow Product Transitions
5d ago
Vertex Pharmaceuticals price target raised to $499 from $467 at Barclays
Premium
The Fly
Vertex Pharmaceuticals price target raised to $499 from $467 at Barclays
5d ago
Vertex Pharmaceuticals price target lowered to $442 from $450 at Scotiabank
PremiumThe FlyVertex Pharmaceuticals price target lowered to $442 from $450 at Scotiabank
6d ago
Vertex Pharmaceuticals price target raised to $464 from $462 at Morgan Stanley
Premium
The Fly
Vertex Pharmaceuticals price target raised to $464 from $462 at Morgan Stanley
6d ago
Optimistic Outlook for Vertex Pharmaceuticals Driven by Strong Market Penetration and Strategic Clinical Advancements
Premium
Ratings
Optimistic Outlook for Vertex Pharmaceuticals Driven by Strong Market Penetration and Strategic Clinical Advancements
6d ago
Vertex Pharmaceuticals downgraded to Market Perform from Outperform at Leerink
PremiumThe FlyVertex Pharmaceuticals downgraded to Market Perform from Outperform at Leerink
6d ago
Vertex Pharmaceuticals: Strong Market Performance and Promising Future Prospects Reinforce Buy Rating
Premium
Ratings
Vertex Pharmaceuticals: Strong Market Performance and Promising Future Prospects Reinforce Buy Rating
6d ago
Vertex Pharmaceuticals: Strong Fundamentals and Promising Future Despite Short-term Challenges
Premium
Ratings
Vertex Pharmaceuticals: Strong Fundamentals and Promising Future Despite Short-term Challenges
6d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100